Target family: NOD-like receptor family (type: catalytic_receptor)
Target: NLRP3

Ligand: NT-0796 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.489999771118164 pIC50
Reference (Journal): Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders.
Published in: J Med Chem

Ligand: compound 15z [PMID: 38029358] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.889999866485596 pIC50
Reference (Journal): Discovery of Novel 2,3-Dihydro-1<i>H</i>-indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis.
Published in: J Med Chem

Ligand: compound 15z [PMID: 38029358] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.989999771118164 pKd
Reference (Journal): Discovery of Novel 2,3-Dihydro-1<i>H</i>-indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis.
Published in: J Med Chem

Ligand: CP-424,174 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.590000152587891 pIC50
Reference (Journal): Inhibiting the Inflammasome: A Chemical Perspective.
Published in: J Med Chem

Ligand: CY-09 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pKd
Reference (Journal): Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders.
Published in: J Exp Med

Ligand: dapansutrile (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.
Published in: Proc Natl Acad Sci USA

Ligand: emlenoflast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.849999904632568 pIC50
Reference (Patent): Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide

Ligand: GDC-2394 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.289999961853027 pIC50
Reference (Journal): Overcoming Preclinical Safety Obstacles to Discover (<i>S</i>)-<i>N</i>-((1,2,3,5,6,7-Hexahydro-<i>s</i>-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5<i>H</i>-pyrazolo[5,1-<i>b</i>][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor.
Published in: J Med Chem

Ligand: MCC950 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
Published in: Nat Med

Ligand: NDT-19795 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.179999828338623 pIC50
Reference (Journal): Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders.
Published in: J Med Chem

Ligand: nibrozetone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.
Published in: Drugs

Ligand: NT-0249 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.960000038146973 pIC50
Reference (Journal): Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796.
Published in: J Pharmacol Exp Ther